Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
Phone410-581-8042
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$501 million
Profitability
Miscellaneous
Employees420
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Medifast (NYSE:MED) Frequently Asked Questions
What is Medifast's stock symbol?
Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."
How often does Medifast pay dividends? What is the dividend yield for Medifast?
Medifast announced a -- dividend on Friday, September 13th. Investors of record on Friday, September 27th will be paid a dividend of $0.75 per share on Thursday, November 7th. This represents a dividend yield of 2.8%. The ex-dividend date is Thursday, September 26th. View Medifast's Dividend History.
How were Medifast's earnings last quarter?
Medifast Inc (NYSE:MED) issued its earnings results on Thursday, November, 7th. The specialty retailer reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.33 by $0.01. The specialty retailer had revenue of $190.10 million for the quarter, compared to the consensus estimate of $194.70 million. Medifast had a net margin of 10.70% and a return on equity of 62.93%. The business's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. View Medifast's Earnings History.
When is Medifast's next earnings date?
What guidance has Medifast issued on next quarter's earnings?
Medifast updated its fourth quarter earnings guidance on Thursday, November, 7th. The company provided earnings per share guidance of $1.03-.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.04. The company issued revenue guidance of $157-167 million, compared to the consensus revenue estimate of $202.43 million.
What price target have analysts set for MED?
4 equities research analysts have issued twelve-month price objectives for Medifast's shares. Their forecasts range from $74.00 to $216.00. On average, they anticipate Medifast's stock price to reach $140.00 in the next year. This suggests a possible upside of 79.5% from the stock's current price. View Analyst Price Targets for Medifast.
What is the consensus analysts' recommendation for Medifast?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.
Has Medifast been receiving favorable news coverage?
News stories about MED stock have trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medifast earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Medifast.
Are investors shorting Medifast?
Medifast saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,780,000 shares, an increase of 6.5% from the September 30th total of 3,550,000 shares. Based on an average daily volume of 366,600 shares, the days-to-cover ratio is currently 10.3 days. Approximately 33.1% of the shares of the stock are short sold. View Medifast's Current Options Chain.
Who are some of Medifast's key competitors?
What other stocks do shareholders of Medifast own?
Who are Medifast's key executives?
Medifast's management team includes the folowing people:
- Mr. Daniel R. Chard, CEO & Director (Age 54)
- Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
- Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
- Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
- Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)
Who are Medifast's major shareholders?
Medifast's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (2.89%), Ingalls & Snyder LLC (0.49%), Russell Investments Group Ltd. (0.35%), California Public Employees Retirement System (0.30%), Rhumbline Advisers (0.30%) and Chickasaw Capital Management LLC (0.28%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.
Which major investors are selling Medifast stock?
MED stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, California Public Employees Retirement System, State of Tennessee Treasury Department, Great West Life Assurance Co. Can, Eqis Capital Management Inc., Robeco Institutional Asset Management B.V., Chicago Equity Partners LLC and First Quadrant L P CA. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano, Constance J Hallquist and Scott Schlackman. View Insider Buying and Selling for Medifast.
Which major investors are buying Medifast stock?
MED stock was acquired by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Garnet Equity Capital Holdings Inc., First Trust Advisors LP, State of Alaska Department of Revenue, Campbell Newman Asset Management Inc., Virginia Retirement Systems ET AL, Palouse Capital Management Inc. and Tower Research Capital LLC TRC . Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.
How do I buy shares of Medifast?
Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medifast's stock price today?
One share of MED stock can currently be purchased for approximately $77.98.
How big of a company is Medifast?
Medifast has a market capitalization of $905.29 million and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.
What is Medifast's official website?
How can I contact Medifast?
Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]
MarketBeat Community Rating for Medifast (NYSE MED)
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
